Search results
Results from the WOW.Com Content Network
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]
Already a multibillion-dollar market, one researcher believes the lupus nephritis treatment market will grow at 11% a year through 2033 to $5.7 billion. Artiva hopes to use the treatment for ...
Kadmon Corporation (originally Kadmon Pharmaceuticals) is a biopharmaceutical company based in New York City.It also has operations in Warrendale, PA and Brighton, MA.The company was founded in 2009 by Samuel D. Waksal, [2] [3] founder and former CEO of ImClone Systems, a company now fully merged into Eli Lilly.
In May 2014, Kite Pharma filed a registration with the SEC for an initial public offering (IPO) of its common stock. [45] In June 2014, Kite Pharma sold 8,625,000 shares of its common stock in their IPO at $17.00 per share, for gross proceeds of $146.6 million. [46] [47] [48] The company listed on the NASDAQ Global market under the symbol ...
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.The company has three commercially approved medicines: Spinraza (), Tegsedi (), and Waylivra (Volanesorsen), and has four drugs in pivotal studies: tominersen for Huntington's disease (together with Roche), tofersen for SOD1-ALS, AKCEA ...
Previous logo. Companies which PureTech Health founded include Karuna Pharmaceuticals, [4] Gelesis, which has received FDA approval as a treatment for weight management, [5] Akili Interactive Labs, which is developing a digital therapeutic platform for cognitive disorders, [6] Vedanta Biosciences, which is developing drugs to treat autoimmune and inflammatory diseases, [7] and Follica which is ...
[2] [3] In 2008 in response to shareholder pressure, PDL spun out its active development programs to a company called Facet Biotech that it capitalized with $400 million. [ 4 ] [ 5 ] Protein Design Labs, founded in 1986 [ 5 ] by cell biologist Laurence J. Korn and mathematician Cary Queen, [ 6 ] was a pioneer in humanizing monoclonal antibodies .
[citation needed] Avalanche went public through an IPO in 2014, raising $102 million. [6] In 2015, co-founder Tom Chalberg stepped down as CEO following Phase IIa trial results that were labeled as "iffy". [7] In May 2016, Avalanche acquired Annapurna Therapeutics and changed its name to Adverum Biotechnologies. [8]